P. Germonpré

发表

Inhaled treatment of COPD: a Delphi consensus statement

G. Joos, V. Ninane, W. Janssens, 2016, International journal of chronic obstructive pulmonary disease.

Serial Measurements of Mesothelioma Serum Biomarkers in Asbestos-Exposed Individuals: A Prospective Longitudinal Cohort Study

S. Vansteelandt, K. Nackaerts, J. V. van Meerbeeck, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Preferred and actual involvement of advanced lung cancer patients and their families in end-of-life decision making: a multicenter study in 13 hospitals in Flanders, Belgium.

L. Deliens, J. Bernheim, R. Deschepper, 2012, Journal of Pain and Symptom Management.

Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma

K. Nackaerts, E. Kellen, J. V. van Meerbeeck, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).

J. Milanowski, C. Gridelli, D. Atanackovic, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Gefitinib monotherapy in advanced non-small cell lung cancer (NSCLC): Experience from a large, Western community implementation study

K. Nackaerts, J. Canon, J. Vansteenkiste, 2006 .

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer

D. Gerber, I. Bondarenko, W. Su, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

Yan Sun, Li Zhang, John V Heymach, 2010, The Lancet. Oncology.

Endobronchial Lipomas: Rare Benign Lung Tumors, Two Case Reports

E. van Marck, P. Germonpré, A. Janssens, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial.

R. Govindan, M. Ranson, N. Rizvi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC).

R. Herbst, N. Saijo, B. Johnson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sensory neuropeptides and the human lower airways: present state and future directions.

R. Pauwels, G. Joos, J. Kips, 1994, The European respiratory journal.

Neurogenic inflammation in human airways: is it important?

R. Pauwels, G. Joos, P. Germonpré, 1995, Thorax.

Glucocorticosteroids as antioxidants in treatment of asthma and COPD New application for an old medication?

W. Backer, P. Germonpré, A. Sadowska, 2007, Steroids.

Malignant pleural mesothelioma with heterologous osteoblastic elements: computed tomography, magnetic resonance, and positron emission tomography imaging characteristics of a rare tumor.

E. van Marck, P. Parizel, R. Salgado, 2005, Journal of computer assisted tomography.

Presence of substance P and neurokinin 1 receptors in human sputum macrophages and U-937 cells.

R. Pauwels, B. Lambrecht, G. Joos, 1999, The European respiratory journal.

Trovafloxacin Concentrations in Airway Fluids of Patients with Severe Community-Acquired Pneumonia

R. Pauwels, P. Germonpré, R. Peleman, 2000, Antimicrobial Agents and Chemotherapy.

Modulation by 5‐HT1A receptors of the 5‐HT2 receptor‐mediated tachykinin‐induced contraction of the rat trachea in vitro

R. Pauwels, G. Joos, P. Germonpré, 1998, British journal of pharmacology.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC).

R. Herbst, N. Saijo, B. Johnson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation

S. Hunt, R. Pauwels, B. Lambrecht, 1999 .

Role of the 5-HT receptor in neurogenic inflammation in Fisher 344 rat airways.

R. Pauwels, G. Joos, P. Germonpré, 1997, European journal of pharmacology.

Characterization of neurogenic inflammation in the airways of two highly inbred rat strains.

R. Pauwels, G. Joos, J. Kips, 1995, American journal of respiratory and critical care medicine.

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

A. Navarro, R. Huber, M. Thomas, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

O-103 A comparison of the antitumour efficacy of ZD6474 and gefitinib(Iressa™) in patients with NSCLC: Results of a randomized, double-blind Phase II study

R. Govindan, M. Ranson, N. Rizvi, 2005 .

Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals.

M. Thomeer, N. De Brucker, K. Tournoy, 2018, Lung cancer.

Preferences of patients with advanced lung cancer regarding the involvement of family and others in medical decision-making.

L. Deliens, J. Bernheim, R. Deschepper, 2010, Journal of palliative medicine.

Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation.

S. Hunt, R. Pauwels, B. Lambrecht, 1999, European journal of immunology.

Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma.

Tsung-Teh Wu, Paul Germonpré, J. Herman, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Expressed wishes and incidence of euthanasia in advanced lung cancer patients

L. Deliens, J. Bernheim, R. Deschepper, 2012, European Respiratory Journal.

Changing preferences for information and participation in the last phase of life: a longitudinal study among newly diagnosed advanced lung cancer patients

L. Deliens, J. Bernheim, R. Deschepper, 2012, Supportive Care in Cancer.

Characterization of the neurogenic plasma extravasation in the airways.

R. Pauwels, G. Joos, P. Germonpré, 1995, Archives internationales de pharmacodynamie et de therapie.

ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.

P. V. Van Schil, J. V. van Meerbeeck, P. Pauwels, 2014, Translational lung cancer research.

Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.

K. Nackaerts, E. Kellen, J. V. van Meerbeeck, 2010, American journal of respiratory and critical care medicine.

Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.

E. Giovannetti, J. V. van Meerbeeck, P. Pauwels, 2014, Cancer treatment reviews.

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.

R. Govindan, M. Ranson, N. Rizvi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.

G. Scagliotti, Keunchil Park, F. de Marinis, 2010, Lung cancer.

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.

H. Groen, F. Cappuzzo, E. Felip, 2015, Lung cancer.

Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC

E. Giovannetti, G. Peters, D. Gandara, 2018, Clinical lung cancer.

Rapid-onset adult respiratory distress syndrome after activated charcoal aspiration. A pitch-black tale of a potential to kill.

P. Jorens, A. Snoeckx, P. Germonpré, 2015, American journal of respiratory and critical care medicine.

A Multicenter Study to Assess EGFR Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical Setting

J. V. van Meerbeeck, P. Pauwels, C. Rolfo, 2018, Cancers.

Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability

P. Germonpré, T. Van den Wyngaert, P. Germonpre, 2019, PloS one.

Customizing systemic therapy in patients with advanced non-small cell lung cancer

W. De Backer, P. Germonpré, A. Janssens, 2011, Therapeutic advances in medical oncology.

Routine implementation of EGFR mutation testing in clinical practice in Flanders: ‘HERMES’ project

J. V. van Meerbeeck, P. Pauwels, M. Kockx, 2014, Acta clinica Belgica.

Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study

K. Cuppens, S. Ocak, L. Decoster, 2021, Drugs - Real World Outcomes.

Validation of computational fluid dynamics in CT-based airway models with SPECT/CT.

Wilfried De Backer, Paul M Parizel, Paul Germonpré, 2010, Radiology.

Antineoplastic therapy-induced pulmonary toxicity

M. Peeters, P. Germonpré, P. Specenier, 2013, Expert review of anticancer therapy.

Flow analyses in the lower airways: patient-specific model and boundary conditions.

F L Wuyts, P M Parizel, P. Parizel, 2008, Medical engineering & physics.

The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor.

K. Nackaerts, E. Kellen, J. V. van Meerbeeck, 2012, Chest.

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer

E. Giovannetti, G. Peters, P. Pauwels, 2016, World journal of clinical oncology.

Postextubation Obstructive Pseudomembranes: A Case Series and Review of a Rare Complication After Endotracheal Intubation

P. Pauwels, P. Jorens, P. Germonpré, 2011, Lung.

Neural mechanisms in asthma.

R. Pauwels, G. Joos, P. Germonpré, 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Are patients’ preferences for information and participation in medical decision-making being met? Interview study with lung cancer patients

L. Deliens, J. Bernheim, R. Deschepper, 2011, Palliative medicine.

Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study

K. Nackaerts, J. Canon, J. Vansteenkiste, 2006, European Respiratory Journal.

Use of ICAM-1 antibodies and antisense oligonucleotides to inhibit transmigration of neutrophils

W. De Backer, P. Germonpré, Frans J van Overveld, 2004, Inflammation Research.

Nodal status at repeat mediastinoscopy determines survival in non-small cell lung cancer with mediastinal nodal involvement, treated by induction therapy.

P. V. Van Schil, J. Hendriks, P. Germonpré, 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Computational fluid dynamics can detect changes in airway resistance in asthmatics after acute bronchodilation.

F L Wuyts, P M Parizel, P. Parizel, 2008, Journal of biomechanics.

Remediastinoscopy after neoadjuvant therapy for non-small cell lung cancer.

P. V. Van Schil, P. Schil, P. Germonpré, 2002, Lung cancer.

Prognostic Factors of Spinal Cord Decompression Sickness in Recreational Diving: Retrospective and Multicentric Analysis of 279 Cases

M. Hugon, B. Delafosse, M. Coulange, 2011, Neurocritical care.

The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies

E. Giovannetti, P. V. Van Schil, P. Pauwels, 2019, Molecules.

Inhaled treatment of COPD: a Delphi consensus statement

G. Joos, V. Ninane, W. Janssens, 2016, International journal of chronic obstructive pulmonary disease.

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.

A Vergnenegre, X. Chen, X. Qian, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.